Establishment of a Early Risk Model of ECMO in Children With ARDS

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

95 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-01-01

Study Completion Date

2022-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The key problem in the treatment of ARDS is refractory hypoxemia. Extracorporeal Membrane Oxygenation (ECMO) is an extracorporeal oxygenation of venous blood to eliminate carbon dioxide and return to the body. It has been an important part of the rescue treatment for ARDS. This study intends to explore the timing of ECMO. The main research hypothesis is that the appropriate timing of ECMO treatment can improve the weaning success rate and survival rate of children with severe ARDS; it is expected to provide a basis for determining the best timing of ECMO treatment

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

ECMO for Critically Ill Patients With Respiratory Failure and/or Circulatory Failure

NCT04031794

Severe Acute Respiratory Distress Syndrome Refractory Hypoxemia

UNKNOWN

Extracorporeal Membrane Oxygenation (ECMO)

NCT03607760

Extracorporeal Membrane Oxygenation

COMPLETED

Clinical Studies of the Effects of Extracorporeal Membrane Oxygenation for Severe ARDS Mortality

NCT01677117

ECMO Treatment

UNKNOWN

Invasive Ventilation Strategies for Neonates With Acute Respiratory Distress Syndrome Syndrome (ARDS)

NCT03372525

Acute Respiratory Distress Syndrome Bronchopulmonary Dysplasia High Frequency Oscillation Ventilation

UNKNOWN NA

Prone Position During ECMO in Pediatric Patients With Severe ARDS

NCT06369584

Pediatric Acute Respiratory Distress Syndrome Extracorporeal Membrane Oxygenation

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Severe acute respiratory distress syndrome (ARDS), especially those caused by severe viral pneumonia, is still an important factor in the death of children, with a case fatality rate of 55%. The treatment includes lung protective ventilation and advanced ventilation support, but the effect is still not ideal for severe patients. ECMO can effectively support the respiratory system and provide good oxygen exchange. However, the survival rate of ECMO treatment in children with ARDS has a large bias.One of the key factors is the uneven timing of ECMO activation, which significantly affects the prognosis.This study intends to design a multi-center, prospective, non-randomized controlled trial , through retrospective research to find relevant factors affecting the prognosis of ECMO treatment, and to screen key indicators related to the timing of intervention; through a prospective cohort study to screen Good indicators and cut-off values suitable for starting ECMO , constructing and verifying comprehensive prediction models.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

ARDS

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ARDS children

children with severe ARDS

ECMO

Intervention Type PROCEDURE

VV-ECMO

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ECMO

VV-ECMO

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Acute onset; within 7 days of clinical insult
* Chest imaging (radiograph or computed tomography) findings of new infiltrates (unilateral or bilateral) consistent with acute parenchymal disease
* Edema not fully explained by fluid overload or cardiac failure
* May present as new acute lung disease in setting of chronic lung disease and/or heart disease
* OI≥16
* Viral etiology is clear

Exclusion Criteria

* Perinatal lung disease
* Large intracranial bleed with mass effect or need for neurosurgical intervention
* Hypoxic cardiac arrest without adequate CPR
* Irreversible underlying cardiac or lung pathology (and not a transplant candidate)
* Pulmonary hypertension and chronic lung disease
* Chronic multiorgan dysfunction
* Incurable malignancy
* Allogenic bone marrow recipients with pulmonary infiltrates
* Hepatic or renal failure
* Pertussis infection in infants
* Fungal pneumonia
* Immunodeficiency

Minimum Eligible Age

28 Days

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No